Ovation owns a unique population-scale biobank of consented and linkable disease-specific biospecimens, which includes more than 1.6 million samples from over...
The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in...
LEUVEN, Belgium, Sept. 5, 2024 /PRNewswire/ -- P95 BV ("P95"), a leading global provider of epidemiology and clinical solutions with a specialty...
New capabilities and simple, standard site experience cut trial time and expense Fixed price implementation to get up and running...
Halifax, Nova Scotia--(Newsfile Corp. - September 5, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")...
CE Mark approval opens European market for TRUVIEW system ANN ARBOR, MI / ACCESSWIRE / September 5, 2024 / Zomedica...
ATLANTA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet...
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage...
MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),...
Planegg/Martinsried, September 5, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on...
SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its...
BASKING RIDGE, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Fort Lee, NJ, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage...
Voyager to receive upfront consideration of $15 million and is eligible to receive up to $305 million in potential associated...
Curated data show expression of PDE4B above a specific measurable threshold observed in 70% of adult colitis patients and 90%...
EMERYVILLE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage...
Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial...
NANJING, China, Sept. 5, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets...
CluePoints Supports Launch of RBQMLive 2024 as Premier Event Sponsor KING OF PRUSSIA, Pa., Sept. 4, 2024 /PRNewswire/ -- CluePoints,...
PHILADELPHIA, Sept. 4, 2024 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today it...